Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AlphaRx, Inc.
Positive phase I trial results reported for Indaflex
July 6th, 2005
AlphaRx, Inc., (ALRX.OB - News) reported positive results from the company's phase I human trial for its lead pharmaceutical product Indaflex, a topical treatment for arthritis. AlphaRx plans to initiate a phase II study of Indaflex in the third quarter of 2005. The study was a phase I open-label, single and multiple dose, non-randomized, 2-way crossover, single center clinical trial. The primary objective of this study was to evaluate the safety and tolerability of single and multiple-dose applications of Indaflex, a novel formulation of Indomethacin cream. The secondary objective of this study was to evaluate the relative bioavailability between...
Source: Biotech Week (2005-07-06)
|
